The following prognostic factors were selected: performance status (Eastern Cooperative Oncology Group), tumor location, decompression for BTS, change in decompression method, depth of invasion, lymph node metastasis, postoperative complication, adjuvant chemotherapy, serum CEA level, serum CA 19-9 level, and NLR. This evidence concerns the gene CEACAM5 and metastatic malignant neoplasm in the lymph nodes.